Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053917 · ClinicalTrials.gov registry record · Phase 1
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
A Phase 1 study of Stroke and Ischemic Stroke, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07053917: Recruiting Phase 1 study of Stroke and Ischemic Stroke, sponsored by Johns Hopkins University.
NCT07053917 is a Phase 1 study of Stroke and Ischemic Stroke that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 20 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07053917, a Phase 1 study of Stroke and Ischemic Stroke, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.
Primary Outcome
Will be measuring the number of participants that meet these criteria: 1. no sustained elevation of systolic blood pressure of more than 180 mmHg on more than two readings sustained for more than 20 minutes. 2. no sustained elevation of diastolic blood pressure of more that 120 mmHg on more than two reading sustained for more than 20 minutes. 3. No sustained reduction of systolic blood pressure of less than 70 mmHg on more than two readings sustained for more than 20 minutes. 4. No sustained re
Conditions Studied
Interventions
- DRUG Psilocybin (Usona Institute)
Study Locations (1)
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT07053917 shows while recruiting
NCT07053917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).
The record links to 10 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin (Usona Institute) is the first listed.
NCT07053917 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07053917 about?
NCT07053917 is a clinical study titled "Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability". The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.
What is the current status of trial NCT07053917?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-09. Estimated completion is 2027-03.
What conditions does trial NCT07053917 study?
This clinical trial studies the following conditions: Stroke, Ischemic Stroke, Chronic Stroke, Intracerebral Haemorrhage, Hemiparesis After Stroke.
What interventions are being tested in trial NCT07053917?
The interventions under investigation include: Psilocybin (Usona Institute) (DRUG).
Who is sponsoring clinical trial NCT07053917?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053917 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07053917's enrollment target sits among peer trials
20 361st of 454 higher than 74 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
RECRUITING · Phase 1
-
Hybrid Robot+FES Stroke Rehabilitation
RECRUITING · Phase 1
-
Vibrotactile Stimulation for Upper-Extremity Stroke Rehabilitation
RECRUITING · Phase 1
-
Facilitating Neuroplastic Changes of Acute Stroke Survivors
RECRUITING · Phase 1
-
Identifying Personalized Brain States Predicting Residual Corticospinal Tract Output After Stroke
RECRUITING · Phase 1
-
Accelerated rTMS vs. Sham for Stroke Apathy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI